Search Results for "prothrombin complex concentrate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for prothrombin complex concentrate. Results 11 to 15 of 15 total matches.
See also: Beriplex, Kcentra

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
the INR in 12-24 hours; for major bleeding or emergent surgery, 4-factor prothrombin complex concentrate ...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 |  Show IntroductionHide Introduction

Antithrombotic Drugs

   
The Medical Letter on Drugs and Therapeutics • Oct 27, 2014  (Issue 1454)
anticoagulant effect may be reversed by prothrombin complex concentrate and clinical studies of a reversal ...
Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.
Med Lett Drugs Ther. 2014 Oct 27;56(1454):103-8 |  Show IntroductionHide Introduction

Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant

   
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015  (Issue 1465)
for these new drugs, but their anticoagulant effect may be reversed by prothrombin complex concentrate ...
The FDA has approved edoxaban (Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the fourth new oral anticoagulant to be approved for VTE and nonvalvular atrial fibrillation.
Med Lett Drugs Ther. 2015 Mar 30;57(1465):43-5 |  Show IntroductionHide Introduction

Fondaparinux (Arixtra), A New Anticoagulant

   
The Medical Letter on Drugs and Therapeutics • May 13, 2002  (Issue 1130)
. MECHANISM OF ACTION — Heparins act by forming a complex with plasma antithrombin that is more active than ...
Fondaparinux (Arixtra - Organon Sanofi-Synthelabo), a synthetic analog of heparin, has been approved by the FDA for prevention of deep vein thrombosis (DVT) after hip fracture surgery or knee or hip replacement.
Med Lett Drugs Ther. 2002 May 13;44(1130):43-4 |  Show IntroductionHide Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024  (Issue 1693)
receive IV vitamin K and 4-factor prothrombin complex concentrate (4F-PCC).1 DOACs — The direct thrombin ...
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8   doi:10.58347/tml.2024.1693a |  Show IntroductionHide Introduction